Robert E. Landry - 27 Dec 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
27 Dec 2023
Net transactions value
-$407,916
Form type
4
Filing time
29 Dec 2023, 16:05:59 UTC
Previous filing
14 Dec 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $284,235 +750 +3.5% $378.98* 22,111 27 Dec 2023 Direct
transaction REGN Common Stock Tax liability $472,738 -542 -2.5% $872.21 21,569 27 Dec 2023 Direct
transaction REGN Common Stock Options Exercise $322,133 +850 +3.9% $378.98* 22,419 28 Dec 2023 Direct
transaction REGN Common Stock Tax liability $541,547 -612 -2.7% $884.88 21,807 28 Dec 2023 Direct
holding REGN Common Stock 270 27 Dec 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -750 -3.9% $0.000000 18,587 27 Dec 2023 Common Stock 750 $378.98 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -850 -4.6% $0.000000 17,737 28 Dec 2023 Common Stock 850 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.